Belpointe Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-8,852
| Closed | -$1.12M | – | 998 |
|
|
2024
Q4 | $1.12M | Buy |
+8,852
| New | +$1.12M | 0.07% | 280 |
|
|
2024
Q3 | – | Sell |
-8,113
| Closed | -$1.12M | – | 970 |
|
|
2024
Q2 | $1.12M | Buy |
8,113
+3,877
| +92% | +$534K | 0.08% | 243 |
|
|
2024
Q1 | $584K | Buy |
+4,236
| New | +$584K | 0.04% | 400 |
|
|
2023
Q2 | – | Sell |
-756
| Closed | -$76.5K | – | 2324 |
|
|
2023
Q1 | $76.5K | Buy |
756
+267
| +55% | +$27K | ﹤0.01% | 1462 |
|
|
2022
Q4 | $58.4K | Buy |
+489
| New | +$58.4K | ﹤0.01% | 1511 |
|